Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

2. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email (...) Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients

2016 American Heart Association

3. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication Final Update Summary: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication Release Date: November 2016 (...) Recommendation Summary Population Recommendation Grade Adults aged 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 10% or greater The USPSTF recommends that adults without a history of cardiovascular disease (CVD) (ie, symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they have 1

2016 U.S. Preventive Services Task Force

4. Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use

Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Prescrire IN ENGLISH - Spotlight ''Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use '', 1 July 2018 {1} {1} {1} | | > > > Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use FEATURED REVIEW Given its weak efficacy and sometimes serious adverse effects, the harm-benefit balance of statin therapy in primary cardiovascular prevention is uncertain and close to neutral. Much else can be done to reduce

2018 Prescrire

5. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. (PubMed)

Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. Poststroke osteoporosis and consequent fractures increase the risk of morbidity and mortality and cause considerable socioeconomic burden.To evaluate the association between statin use and risks of osteoporosis and fracture in stroke patients.Population-based propensity score‒matched cohort study.Taiwan's National Health Insurance Research Database.Patients newly diagnosed with a stroke between 2000 (...) and 2012 were identified. After propensity score matching, 5254 patients were included, with 2627 patients in the statin and nonstatin cohorts, respectively.Hazard ratios (HRs) for poststroke osteoporosis, hip fracture, and vertebral fracture (together, the primary outcome) were calculated using Cox proportional hazards regression models according to statin use status.Poststroke statin use was associated with a lower overall risk of the primary outcome [adjusted hazard ratio (aHR) = 0.66; P < 0.001

2018 Journal of Clinical Endocrinology and Metabolism

6. Cholesterol: slightly higher risk of type 2 diabetes with all statins

Cholesterol: slightly higher risk of type 2 diabetes with all statins Prescrire IN ENGLISH - Spotlight ''Cholesterol: slightly higher risk of type 2 diabetes with all statins'', 1 January 2017 {1} {1} {1} | | > > > Cholesterol: slightly higher risk of type 2 diabetes with all statins Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Cholesterol (...) : slightly higher risk of type 2 diabetes with all statins Several large-scale studies have revealed an increased risk of type 2 diabetes in patients taking a statin. Statins are widely used to lower cholesterol, in the hope of reducing the risk of premature death and major cardiovascular events (myocardial infarction, ischaemic stroke). A review has been carried out of 13 studies which included patient follow-up for at least one year. Some 91,000 non-diabetic participants were monitored for 4 years

2017 Prescrire

7. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials

Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

8. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis

Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

9. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. (PubMed)

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. To assess whether statin treatment is associated with a reduction in atherosclerotic cardiovascular disease (CVD) and mortality in old and very old adults with and without diabetes.Retrospective cohort study.Database of the Catalan primary care system (SIDIAP), Spain, 2006-15.46 864 people aged 75 years or more without clinically (...) recognised atherosclerotic CVD. Participants were stratified by presence of type 2 diabetes mellitus and as statin non-users or new users.Incidences of atherosclerotic CVD and all cause mortality compared using Cox proportional hazards modelling, adjusted by the propensity score of statin treatment. The relation of age with the effect of statins was assessed using both a categorical approach, stratifying the analysis by old (75-84 years) and very old (≥85 years) age groups, and a continuous analysis

Full Text available with Trip Pro

2018 BMJ

10. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

11. Primary Prevention With Statins in the Elderly. (PubMed)

Primary Prevention With Statins in the Elderly. The burden of atherosclerotic cardiovascular disease (ASCVD) in high-income countries is mostly borne by the elderly. With increasing life expectancy, clear guidance on sensible use of statin therapy to prevent a first and potentially devastating ASCVD event is critically important to ensure a healthy aging population. Since 2013, 5 major North American and European guidelines on statin use in primary prevention of ASCVD have been released (...) by the American College of Cardiology/American Heart Association, the UK National Institute for Health and Care Excellence, the Canadian Cardiovascular Society, U.S. Preventive Services Task Force, and the European Society of Cardiology/European Atherosclerosis Society. Guidance on using statin therapy in primary ASCVD prevention in the growing elderly population (>65 years of age) differs markedly. The authors discuss the discrepant recommendations, place them into the context of available evidence

Full Text available with Trip Pro

2018 Journal of the American College of Cardiology

12. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients Mills E J, Rachlis B, Wu P, Devereaux P J, Arora P, Perri D CRD summary (...) This review concluded that statin treatment used for the primary prevention of cardiovascular disease was effective in reducing cardiovascular death and other major cardiovascular events. The conduct and reporting of the review were good and the conclusions are likely to be reliable. Authors' objectives To assess the effects of statins in primary prevention of cardiovascular events. Searching MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, AMED, CINAHL, TOXNET, Development

Full Text available with Trip Pro

2008 DARE.

13. Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men. (PubMed)

Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men. We sought to determine whether statin use for primary prevention is associated with a lower risk of cardiovascular events or mortality in older men.Prospective cohort study.Physicians' Health Study participants.7,213 male physicians ≥70 years without a history of cardiovascular disease (CVD).Multivariable propensity score for statin use with greedy matching (1:1) to minimize confounding by indication.Median (...) baseline age was 77 (70-102), median follow-up was 7 years. Non-users were matched to 1,130 statin users. Statin use was associated with an 18% lower risk of all-cause mortality, HR 0.82 (95% CI 0.69-0.98) and non-significant lower risk of CVD events, HR 0.86 (95% CI 0.70-1.06) and stroke, HR 0.70 (95% CI 0.45-1.09). In subgroup analyses, results did not change according to age group at baseline (70-76 or >76 years) or functional status. There was a suggestion that those >76 at baseline did not benefit

Full Text available with Trip Pro

2017 Journal of the American Geriatrics Society

14. Does co-enzyme Q10 reduce statin-related muscle pain?

Does co-enzyme Q10 reduce statin-related muscle pain? Does co-enzyme Q10 reduce statin-related muscle pain? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2016\/08\/mo-aug2016cover.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Aug 08 2016 Does co-enzyme Q10 reduce statin-related muscle pain (...) ? By in , , , , , Journal reference: Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015 Jan;90(1):24-34. Link: Published: January 2015 Evidence cookie says… The effect of CoQ10 on muscle pain in people on statin therapy is uncertain. The research evidence is of limited quality and inconsistent. The range of best estimates includes no effect. CoQ10 cannot be recommended as a matter of routine supplementation

2016 Morsels of Evidence

15. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

16. Statins in secondary cardiovascular prevention

Statins in secondary cardiovascular prevention Prescrire IN ENGLISH - Spotlight ''Statins in secondary cardiovascular prevention'', 1 September 2017 {1} {1} {1} | | > > > Statins in secondary cardiovascular prevention Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in secondary cardiovascular prevention FEATURED REVIEW What is the evidence (...) for the efficacy of statins in secondary cardiovascular prevention? In which situations are they effective? What are their harms? To answer these questions, we reviewed the available evidence using the standard Prescrire methodology. Free abstract available here; full review (8 pages) available for download by subscribers. Abstract For patients who have already had a cardiovascular event or who have stable angina or peripheral artery disease, the prevention of cardiovascular events ("secondary prevention

2017 Prescrire

17. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis

Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

18. What statins tell us about the mess in evidence based medicine

What statins tell us about the mess in evidence based medicine What statins tell us about the mess in evidence based medicine – Bad Science Search TED Talk Collected Journalism This Nerdy Book This Great Book T-shirts Categories (3) (4) (6) (45) (28) (6) (16) (190) (5) (20) (52) (88) (2) (1) (2) (1) (677) (4) (14) (2) (37) (4) (9) (3) (11) (6) (3) (16) (13) (1) (6) (8) (6) (6) (3) (13) (2) (2) (27) (1) (2) (6) (1) (7) (8) (3) (1) (4) (12) (1) (3) (20) (2) (13) (1) (20) (15) (4) (1) (20) (1) (1 (...) ) (2) (1) (5) (1) (10) (1) (2) (1) (1) (6) (4) (3) (2) (52) (3) (18) (10) (1) June 30th, 2014 by Ben Goldacre in | Sorry to be absent, I’ve about a zillion big things shortly coming to fruition, at which point expect a deluge. Everyone is having kittens about statins and the BMJ at the moment. Here’s what I wrote as a rabid response on the latest BMJ editorial about it, and a disco soundtrack to keep your attention focused: Statins are a mess: we need better data, and shared decision making I have

2014 Bad Science

19. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review

Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD (...) , Chelladurai Y, Robinson KA CRD summary The authors concluded that lower-intensity statins combined with bile acid sequestrant or ezetimibe may be an alternative to higher-intensity statin monotherapy for high-risk statin-intolerant patients or those with a low response to statins; a cautious approach in practice was recommended. The authors' conclusion reflected the evidence presented and is likely to be reliable. Authors' objectives To evaluate the effectiveness of lower intensity statin combination

Full Text available with Trip Pro

2014 DARE.

20. Systematic review with meta-analysis: Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease

Systematic review with meta-analysis: Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease | BMJ Evidence-Based Medicine We use cookies (...) Username * Password * your user name or password? You are here Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease Article Text Therapeutics Systematic review with meta-analysis Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short

2013 Evidence-Based Medicine (Requires free registration)